文献速递乳腺乳腺X线

评估可疑乳腺微钙化的恶性程度:对比增强乳腺摄影的作用

Assessing the malignancy of suspicious breast microcalcifications: the role of contrast enhanced mammography.
PubMed 文献 · Radiol Med · 2024-04-12

该研究回顾性纳入182例患者共184个可疑钙化(BIRADS 4)病灶,评估对比增强乳腺摄影(CEM)预测微钙化恶性的价值。CEM总体敏感度0.70、特异度0.85、阳性预测值0.82、阴性预测值0.76、AUC 0.78;低风险组(BIRADS 4a)阴性预测值达0.98,中高风险组(BIRADS 4b-4c)敏感度0.68。作者认为无强化在低可疑钙化中可作为无病的提示参数,但在中高可疑钙化中活检仍为必需。

要点

  • CEM总体预测微钙化恶性的AUC为0.78,敏感度0.70、特异度0.85。
  • 低风险组(BIRADS 4a)阴性预测值0.98,无强化提示无病。
  • 中高风险组(BIRADS 4b-4c)敏感度0.68,无强化不能排除恶性,活检仍为必需。

核心结论

  • 无强化在低可疑微钙化中可作为无病的提示参数,但在中高可疑微钙化中活检仍为必需;强化可用于区分惰性与侵袭性肿瘤,从而减少过度诊断和过度治疗。

研究设计与样本

  • 回顾性研究,纳入在本机构接受CEM及立体定向真空辅助活检(VAB)的可疑钙化(BIRADS 4)患者182例、病灶184个。

诊断标准与关键数值

  • CEM预测微钙化恶性的总体敏感度0.70、特异度0.85、阳性预测值0.82、阴性预测值0.76、AUC 0.78。
  • 低风险组(BIRADS 4a)敏感度0.89、特异度0.89、阳性预测值0.57、阴性预测值0.98、AUC 0.75。
  • 中高风险组(BIRADS 4b-4c)敏感度0.68、特异度0.80、阳性预测值0.87、阴性预测值0.57、AUC 0.75。
  • 强化恶性病灶(N=52)中61.5%的Ki-67≥20%,38.5%为低Ki-67值。
  • 无强化病灶(N=22)中90.9%的Ki-67<20%,9.1%的Ki-67为高值20%。

临床应用与阅片要点

  • 对低可疑(BIRADS 4a)微钙化,无强化可作为无病的提示参数。
  • 对中高可疑(BIRADS 4b-4c)微钙化,无强化不能排除恶性,活检仍为必需。
  • 强化表现可用于区分惰性与侵袭性肿瘤,有助于减少过度诊断和过度治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To assess the role of contrast-enhanced mammography (CEM) in predicting the malignancy of breast calcifications.

MATERIAL AND METHODS: We retrospectively evaluated patients with suspicious calcifications (BIRADS 4) who underwent CEM and stereotactic vacuum-assisted biopsy (VAB) at our institution. We assessed the sensitivity (SE), specificity (SP), positive predictive value (PPV) and negative predictive value (NPV) of CEM in predicting malignancy of microcalcifications with a 95% confidence interval; we performed an overall analysis and a subgroup analysis stratified into group A-low risk (BIRADS 4a) and group B-medium/high risk (BIRADS 4b-4c). We then evaluated the correlation between enhancement and tumour proliferation index (Ki-67) for all malignant lesions.

RESULTS: Data from 182 patients with 184 lesions were collected. Overall the SE of CEM in predicting the malignancy of microcalcifications was 0.70, SP was 0.85, the PPV was 0.82, the NPV was 0.76 and AUC was 0.78. SE in group A was 0.89, SP was 0.89, PPV was 0.57, NPV was 0.98 and AUC was 0.75. SE in group B was 0.68, SP was 0.80, PPV was 0.87, NPV was 0.57 and AUC was 0.75. Among malignant microcalcifications that showed enhancement (N = 52), 61.5% had Ki-67 ≥ 20% and 38.5% had low Ki-67 values. Among the lesions that did not show enhancement (N = 22), 90.9% had Ki-67 < 20% and 9.1% showed high Ki-67 values 20%.

CONCLUSIONS: The absence of enhancement can be used as an indicative parameter for the absence of disease in cases of low-suspicious microcalcifications, but not in intermediate-high suspicious ones for which biopsy remains mandatory and can be used to distinguish indolent lesions from more aggressive neoplasms, with consequent reduction of overdiagnosis and overtreatment.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Depretto C, D'Ascoli E, Della Pepa G, et al. Assessing the malignancy of suspicious breast microcalcifications: the role of contrast enhanced mammography. Radiol Med. 2024. PMID: 38607514. doi:10.1007/s11547-024-01813-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。